Key result
Advanced cancer (stage IV solid neoplasia) was associated with a 24% incidence of venous thromboembolism and a 3% incidence of atrial fibrillation.
Why the study?
Venous thromboembolism is a leading cause of death in cancer patients with an underestimated incidence, and cancer patients also carry an increased risk of atrial fibrillation.
Observational (n=403)
No
In a real-world cohort of advanced cancer patients, the incidence of VTE was 24% and atrial fibrillation was 3%, highlighting a significant cardiovascular burden where current risk scores are poorly predictive.
Answers are grounded in this paper and cite their sources.
Higher VTE rates in advanced cancer may warrant closer surveillance; leaves open need for prospective prophylaxis trials.
BACKGROUND: Venous thromboembolism is the second leading cause of death in cancer patients and its incidence seems underestimated. In addition, cancer patients have an increased risk of developing atrial fibrillation, which may be the first presentation of cancer itself. The primary aim of this study was to define the incidence of venous thromboembolism (VTE) and atrial fibrillation in a real-word series of advanced cancer patients. METHODS: We performed a retrospective single-institution study on patients diagnosed with stage IV solid neoplasia at the outpatient clinic of the Medical Oncology Unit (Spedali Civili Brescia, Italy), from January to December 2018. RESULTS: A total of 403 patients were enrolled, with a mean age at presentation of 63 years (range 18-85 years). A VTE was observed in 24% of cases, half of which occurred after diagnosis of metastatic neoplasia, with a median time of onset of 5.5 months (range 0-84). About 3% of patients developed atrial fibrillation after cancer diagnosis. In this patient series, no statistically significant differences were found when comparing Khorana and PROTECHT thromboembolic risk scores, both before and after the start of chemotherapy. Overall, about 25% of the patients received anticoagulant therapy; in most cases, the drug of choice was low-molecular-weight heparin (LMWH). CONCLUSION: This study showed for cancer patients a considerably higher incidence of VTE and a comparable incidence of atrial fibrillation than reported in literature. Validated thromboembolic risk scores appear to be poorly predictive, and LMWH remains the most widely used anticoagulant drug.
No takes yet. Share an insight, caveat, or question.
Gurizzan et al. (2020) conducted an observational in Stage IV solid neoplasia (n=403). Stage IV solid neoplasia was evaluated on Incidence of venous thromboembolism (VTE) and atrial fibrillation. Advanced cancer (stage IV solid neoplasia) was associated with a 24% incidence of venous thromboembolism and a 3% incidence of atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: